Unknown

Dataset Information

0

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.


ABSTRACT:

Background

Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier.

Objective

The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea-predominant IBS (IBS-D).

Methods

In this double-blind study, 60 patients were randomly assigned to receive XG + PPT + XOS or placebo for 28 days, then crossed over to the alternative treatment. Patients were followed for 60 days.

Results

At Day 28, a significantly higher proportion of patients starting treatment with XG + PPT + XOS than placebo (87 vs 0%; p = 0.0019) presented normal stools (Bristol Stool Form Scale type 3-4). At Day 56, a significantly higher proportion of patients who crossed over to XG + PPT + XOS than placebo (93% vs 23%; p = 0.0001) presented normal stools. In the group allocated to receive XG + PPT + XOS after placebo, benefits of XG + PPT + XOS were maintained during follow-up. Subjective assessments of abdominal pain, bloating, quality of life and general health indicated significant improvement with XG + PPT + XOS over placebo. There were no related adverse events.

Conclusion

XG + PPT + XOS effectively controlled diarrhoea and alleviated clinical symptoms in patients with IBS-D, and was well tolerated.

SUBMITTER: Trifan A 

PROVIDER: S-EPMC6794699 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Trifan Anca A   Burta Ovidiu O   Tiuca Nicoleta N   Petrisor Diana Corina DC   Lenghel Augustin A   Santos Javier J  

United European gastroenterology journal 20190703 8


<h4>Background</h4>Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier.<h4>Objective</h4>The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea-predominant IBS (IBS-D).<h4>Methods</h4>In this doub  ...[more]

Similar Datasets

| S-EPMC5157770 | biostudies-literature
| S-EPMC5994265 | biostudies-literature
| S-EPMC2795180 | biostudies-literature
| S-EPMC11772933 | biostudies-literature
| S-EPMC7735853 | biostudies-literature
| S-EPMC7383621 | biostudies-literature
| S-EPMC4173656 | biostudies-literature
| S-EPMC4493894 | biostudies-literature
| S-EPMC1726971 | biostudies-other
| S-EPMC3880695 | biostudies-literature